6:25 PM
 | 
Dec 12, 2012
 |  BC Extra  |  Financial News

Acadia to raise $86.4M for second Phase III pimavanserin trial

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) plans to raise $86.4 million in a private placement through the sale of 19 million shares at $4.43 and seven-year warrants to purchase 500,000 shares at...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >